The Journal of Urology 2025

67 papers
The 2025 edition of The Journal of Urology includes 36 papers highlighting advancements in urological oncology, health equity, and digital health integration. Research into prostate cancer is a significant focus, with studies examining urban-rural and racial disparities in the use of intensified systemic therapies and advanced imaging like mpMRI and PET scans. Diagnostic developments include the evaluation of PSMA-PET/CT for molecular-guided nerve sparing and the use of Restriction Spectrum Imaging as a quantitative biomarker. Technological applications are also prominent, featuring the use of generative artificial intelligence for data abstraction in kidney cancer pathology and wearable devices for perioperative home monitoring. In bladder cancer, research explores the efficacy of thermosensitive liposomal doxorubicin combined with hyperthermic intravesical chemotherapy. Molecular studies investigate senescence-associated miRNA in clear cell renal cell carcinoma to better understand the tumor immune microenvironment. Prolific contributors to this year’s volume include Jeremy Yuen-Chun Teoh, Chi-Fai Ng, and Hiten D. Patel, whose work reflects a broader trend toward precision diagnostics and the reduction of healthcare disparities.

Top Research Directions

The 3 research directions with The Journal of Urology 2025 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Calibrating Diagnostic Thresholds for Specific Populations11.5%
2Mitigating Demographic Performance Disparities in Medical Imaging11.5%
3Mitigating Inter-Observer Variability in Medical Diagnostics11.5%

Download all directions as CSV

Institutions

Institutions credited by The Journal of Urology 2025 papers: a paper credits every institution named in its affiliations, once. 6 institutions share 1 credited papers.

#InstitutionPapersShare
100n1w4965 1100.0%
205626m728 1100.0%
3New York University 1100.0%
4Northwestern University 1100.0%
5NYU Langone Health 1100.0%
6University of Illinois Chicago 1100.0%

Download all institutions as CSV

About this data

Papers. The Journal of Urology 2025 lists 67 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 67 papers (1.5%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “The Journal of Urology 2025”, https://lacuna.tiptreesystems.com/venue/the-journal-of-urology/2025.

Top Authors

AuthorPapers
Jeremy Yuen-Chun Teoh10
Alex Qinyang Liu4
Bradford J Wood2
Anobel Odisho1
Jens Kleesiek1
Qi Dou1

Papers

Title
Active Surveillance vs Primary Intervention for Clinical T1a Kidney Tumors: 12-Year Experience of the Delayed Intervention and Surveillance for Small Renal Masses Prospective Comparative Study
GG01-21 DEVELOPING AND VALIDATING AN ADVANCED ARTIFICIAL INTELLIGENCE (AI) SEGMENTATION MODEL TO ASSIST UROLOGISTS IN MRI-ULTRASOUND FUSION BIOPSY
GG01-21 DEVELOPING AND VALIDATING AN ADVANCED ARTIFICIAL INTELLIGENCE (AI) SEGMENTATION MODEL TO ASSIST UROLOGISTS IN MRI-ULTRASOUND FUSION BIOPSY
Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes
IP04-12 IMPACT OF PATIENT TRAVEL TIME ON OVERALL AND PROSTATE CANCER SURVIVAL: FINDINGS FROM A MULTI-STATE REGISTRY COHORT STUDY
IP04-12 IMPACT OF PATIENT TRAVEL TIME ON OVERALL AND PROSTATE CANCER SURVIVAL: FINDINGS FROM A MULTI-STATE REGISTRY COHORT STUDY
IP12-03 CLINICAL VALUE OF PREOPERATIVE PLASMA HER2 AND EPIDERMAL GROWTH FACTOR RECEPTOR IN PATIENTS WITH CLINICALLY LOCALIZED UTUC: A RETROSPECTIVE MULTICENTER COHORT STUDY
IP12-03 CLINICAL VALUE OF PREOPERATIVE PLASMA HER2 AND EPIDERMAL GROWTH FACTOR RECEPTOR IN PATIENTS WITH CLINICALLY LOCALIZED UTUC: A RETROSPECTIVE MULTICENTER COHORT STUDY
IP12-31 THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN COMBINED WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA: A MULTICENTER REAL-WORLD STUDY
IP12-31 THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN COMBINED WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA: A MULTICENTER REAL-WORLD STUDY
IP14-07 THERMOSENSITIVE LIPOSOMAL DOXORUBICIN COMBINED WITH HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
IP14-07 THERMOSENSITIVE LIPOSOMAL DOXORUBICIN COMBINED WITH HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
IP16-12 ARTIFICIAL INTELLIGENCE (AI)-BASED PREDICTION OF RENAL TUMOR GROWTH KINETICS AT CRITICAL TUMOR LENGTHS IN VON HIPPEL-LINDAU (VHL) SYNDROME
IP16-12 ARTIFICIAL INTELLIGENCE (AI)-BASED PREDICTION OF RENAL TUMOR GROWTH KINETICS AT CRITICAL TUMOR LENGTHS IN VON HIPPEL-LINDAU (VHL) SYNDROME
IP16-31 SENESCENCE-ASSOCIATED MIRNA IN CLEAR CELL RENAL CELL CARCINOMA: EXPLORING THE ROLE OF THE TUMOR IMMUNE MICROENVIRONMENT AND PREDICTING SURVIVAL THROUGH SENESCENCE-ASSOCIATED FACTORS
IP16-31 SENESCENCE-ASSOCIATED MIRNA IN CLEAR CELL RENAL CELL CARCINOMA: EXPLORING THE ROLE OF THE TUMOR IMMUNE MICROENVIRONMENT AND PREDICTING SURVIVAL THROUGH SENESCENCE-ASSOCIATED FACTORS
IP21-15 SMART TRIAL: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER BY MRI-TARGETED APPROACH VERSUS 24-CORE TRANSPERINEAL SYSTEMATIC BIOPS
IP21-15 SMART TRIAL: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER BY MRI-TARGETED APPROACH VERSUS 24-CORE TRANSPERINEAL SYSTEMATIC BIOPS
IP21-23 DEEP LEARNING–BASED ARTIFICIAL INTELLIGENCE ALGORITHM FOR PREDICTING PROSTATE CANCER AT PROSTATE BIOPSY AND ITS COMPARISON WITH RADIOLOGISTS USING PIRADS VS 2.1: AN EXTERNAL VALIDATION STUDY
IP21-23 DEEP LEARNING–BASED ARTIFICIAL INTELLIGENCE ALGORITHM FOR PREDICTING PROSTATE CANCER AT PROSTATE BIOPSY AND ITS COMPARISON WITH RADIOLOGISTS USING PIRADS VS 2.1: AN EXTERNAL VALIDATION STUDY
IP24-09 ASSOCIATION BETWEEN TIME FROM DIAGNOSIS TO RADICAL CYSTECTOMY AND ONCOLOGIC OUTCOMES IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
IP24-09 ASSOCIATION BETWEEN TIME FROM DIAGNOSIS TO RADICAL CYSTECTOMY AND ONCOLOGIC OUTCOMES IN MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
IP24-12 PROGNOSTIC VALUE OF PREOPERATIVE DE RITIS RATIO IN PATIENTS TREATED WITH RADICAL CYSTECTOMY
IP24-12 PROGNOSTIC VALUE OF PREOPERATIVE DE RITIS RATIO IN PATIENTS TREATED WITH RADICAL CYSTECTOMY
IP24-35 DEVELOPING A RISK-BASED ONCOLOGICAL FOLLOW-UP STRATEGY FOR BLADDER CANCER PATIENTS AFTER RADICAL CYSTECTOMY
IP24-35 DEVELOPING A RISK-BASED ONCOLOGICAL FOLLOW-UP STRATEGY FOR BLADDER CANCER PATIENTS AFTER RADICAL CYSTECTOMY
IP26-04 VARIATIONS IN METASTATIC PROSTATE CANCER COALTERATION PATTERNS AND PROGNOSTIC IMPLICATIONS FOR SURVIVAL
IP26-04 VARIATIONS IN METASTATIC PROSTATE CANCER COALTERATION PATTERNS AND PROGNOSTIC IMPLICATIONS FOR SURVIVAL
IP26-11 URBAN-RURAL DISPARITIES IN INTENSIFIED SYSTEMIC THERAPIES FOR METASTATIC PROSTATE CANCER: AN ANALYSIS OF MEDICARE CLAIMS
IP26-11 URBAN-RURAL DISPARITIES IN INTENSIFIED SYSTEMIC THERAPIES FOR METASTATIC PROSTATE CANCER: AN ANALYSIS OF MEDICARE CLAIMS
Letter: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value
MP06-16 ARTIFICIAL INTELLIGENCE PREDICTION OF TUMOR GRADE DURING ENDOSCOPIC TREATMENT OF UPPER TRACT UROTHELIAL CARCINOMA: A COMPARISON WITH EXPERTS
MP06-16 ARTIFICIAL INTELLIGENCE PREDICTION OF TUMOR GRADE DURING ENDOSCOPIC TREATMENT OF UPPER TRACT UROTHELIAL CARCINOMA: A COMPARISON WITH EXPERTS
MP06-20 AI-DRIVEN PRECISION: PROSPECTIVE CLINICAL USE OF AN ARTIFICIAL INTELLIGENCE MODEL IN GUIDING PROSTATE BIOPSIES
MP06-20 AI-DRIVEN PRECISION: PROSPECTIVE CLINICAL USE OF AN ARTIFICIAL INTELLIGENCE MODEL IN GUIDING PROSTATE BIOPSIES
MP10-05 TRENDS IN RADICAL TREATMENT OF GRADE GROUP 1 PROSTATE CANCER ACROSS THE VETERANS HEALTH ADMINISTRATION
MP10-05 TRENDS IN RADICAL TREATMENT OF GRADE GROUP 1 PROSTATE CANCER ACROSS THE VETERANS HEALTH ADMINISTRATION
MP13-10 RACIAL DISPARITIES IN THE USE OF MPMRI AND PET SCAN AMONG MEDICARE BENEFICIARIES WITH PROSTATE CANCER
MP13-10 RACIAL DISPARITIES IN THE USE OF MPMRI AND PET SCAN AMONG MEDICARE BENEFICIARIES WITH PROSTATE CANCER
MP16-04 SYSTEMIC TREATMENT PRESCRIPTION AND SWITCH PATTERNS IN MHSPC BASED ON REAL WORLD EVIDENCE: RESULTS FROM THE PIONEER+ BIG DATA CONSORTIUM FOR PROSTATE CANCER
MP16-04 SYSTEMIC TREATMENT PRESCRIPTION AND SWITCH PATTERNS IN MHSPC BASED ON REAL WORLD EVIDENCE: RESULTS FROM THE PIONEER+ BIG DATA CONSORTIUM FOR PROSTATE CANCER
MP23-11 PERIOPERATIVE WEARABLE HOME MONITORING ENHANCES SAME-DAY UROLOGIC SURGERY AND REDUCES UNPLANNED HEALTHCARE UTILIZATION
MP23-11 PERIOPERATIVE WEARABLE HOME MONITORING ENHANCES SAME-DAY UROLOGIC SURGERY AND REDUCES UNPLANNED HEALTHCARE UTILIZATION
MP32-16 MECHANISTIC INSIGHTS INTO SPERMINE WITH HMOX1-INDUCED MITOPHAGY IN PROSTATE CANCER
MP32-16 MECHANISTIC INSIGHTS INTO SPERMINE WITH HMOX1-INDUCED MITOPHAGY IN PROSTATE CANCER
MP36-05 STRANDED BY SHIFTING GUIDELINES: THE BUTTERFLY EFFECT OF USPSTF RECOMMENDATIONS ON PROSTATE CANCER PRESENTATION AND PATHOLOGY
MP36-05 STRANDED BY SHIFTING GUIDELINES: THE BUTTERFLY EFFECT OF USPSTF RECOMMENDATIONS ON PROSTATE CANCER PRESENTATION AND PATHOLOGY
MP36-10 EARLY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER AFTER AN INITIAL NEGATIVE MRI-GUIDED BIOPSY: AN ANALYSIS OF PREDICTIVE FACTORS
MP36-10 EARLY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER AFTER AN INITIAL NEGATIVE MRI-GUIDED BIOPSY: AN ANALYSIS OF PREDICTIVE FACTORS
MP37-19 COMPARATIVE COST ANALYSIS OF ROBOT-ASSISTED SIMPLE PROSTATECTOMY AND HOLMIUM LASER ENUCLEATION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA

Page 1/2 next »